Under Pressure: Sanofi Joins Call For Price Transparency

The pharmaceutical industry's drug pricing problem isn't going away and some drug manufacturers are realizing that the best way they can address the issue is to be more transparent. Educating legislators and even the public about how US drug pricing and the supply chain work, rebating and discounts, and the differences between net and list prices – and backing those conversations up with hard data – won't, at the very least, erode public perception further.

Transparency is a component of the price pledge SanofiCEO Olivier Brandicourt unveiled May 9. Sanofi vowed to limit annual...